Insights on the Solid Tumor Testing Global Market to 2030 - Focus on Technology, Cancer Type, Application, End-user and Competitive Landscape

Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Global Solid Tumor Testing Market 2019-2030: Focus on Technology, Cancer Type, Application, End-user and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

This report highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030.

The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.

The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.

Furthermore, several contract research organizations are focusing on the development of solid tumor testing services, which enable to perform an extensive preclinical study at lower operation costs and less turn-around time.

Within the research report, the market is segmented on the basis of cancer type, technology application, end-users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, companies such as Quest Diagnostics Incorporated have been a pioneer and a significant competitor in this market.

Other key players in the market are Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, Inc., NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health.

On the basis of region, North America holds the largest share of the global solid tumor testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region.

The global solid tumor testing market utilizes technologies such as next-generation sequencing, in-situ hybridization, immunohistochemistry, polymerase chain reaction, and other technologies for the development of advanced diagnostic tools to cater to a holistic approach toward the treatment of cancer. The rising incidence of cancer and the increasing global burden of the disease has subsequently furthered the growth of the market.

Key Questions Answered in this Report

• What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?

• What is the potential impact of biotechnological advancements in the diagnostic industry among end-users such as researchers, pathologists, and laboratory technicians?

• What is the current market demand along with future expected demand for the global solid tumor testing market?

• What are the key development strategies that are implemented by the major players in order to sustain the competitive market?

• How is each segment of the market expected to grow during the forecast period 2020-2030?

• Which are the leading players with significant offerings to the global solid tumor testing market?

• What is the expected market dominance for each of these leading players?

• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market?

Key Topics Covered:

1 Product Definition
1.1 Inclusion and Exclusion

2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Global Solid Tumors Testing Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview
4.1 Definition
4.2 Solid Tumor Testing Technologies
4.3 Industry Participants Landscape
4.4 Impact of COVID-19 on Delivery of Care for Cancer Patients

5 Industry Insights
5.1 Regulation of Genetic Tests
5.1.1 FDA Regulation
5.1.2 CMS Regulation
5.2 Legal Requirements and Framework in Europe
5.3 Legal Requirements and Framework in Asia-Pacific
5.3.1 China
5.3.2 Japan
5.4 Reimbursement Scenario
5.4.1 Impact on Laboratory Industry

6 Market Dynamics
6.1 Impact Analysis
6.2 Market Drivers
6.2.1 Rising Incidence of Cancers
6.2.2 Decreasing Cost of Sequencing
6.2.3 Increasing Adoption of Inorganic Growth Strategies in the Market
6.2.4 Expected Increase in Adoption of Genetic Testing
6.3 Market Restraints
6.3.1 Uncertain Reimbursement Policies
6.3.2 Requirement of High Capital Investment Hindering Expansion
6.3.3 High Pricing Pressure
6.4 Market Opportunities
6.4.1 Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations
6.4.2 Technological Advancements in the Field of Cancer Genomics
6.4.3 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
6.4.4 Increasing Disposable Income in Emerging Economies

7 Competitive Landscape
7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Approvals
7.1.3 Product Launches, Enhancements, and Expansions
7.1.4 Acquisitions and Mergers
7.2 Product Scenario
7.3 Market Share Analysis
7.4 Growth-Share Analysis (Opportunity Mapping)
7.4.1 By Company
7.4.2 By Technology
7.4.3 By Application
7.4.4 By Cancer Type

8 Global Solid Tumor Testing Market (by Technology), $Million, 2019-2030
8.1 Overview
8.2 Next-Generation Sequencing
8.3 In Situ Hybridization
8.4 Polymerase Chain Reaction
8.5 Immunohistochemistry
8.6 Other Technologies

9 Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030
9.1 Overview
9.2 Breast Cancer
9.3 Prostate Cancer
9.4 Colorectal Cancer
9.5 Lung Cancer
9.6 Melanoma
9.7 Endometrial Cancer
9.8 Thyroid Cancer
9.9 Brain Cancer
9.1 Ovarian Cancer
9.11 Liver Cancer
9.12 Other Cancer Types

10 Global Solid Tumor Testing Market, by Application, $Million, 2019-2030
10.1 Overview
10.2 Clinical
10.3 Research

11 Global Solid Tumor Testing Market (by Region), $Million, 2019-2030
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Singapore
11.4.5 Australia
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-LATAM
11.6 Rest-of-the-World (RoW)

12 Global Solid Tumor Testing Market, by End User, $Million, 2019-2030
12.1 Overview
12.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
12.3 Pharmaceutical and Biotechnology Companies
12.4 Contract Research Organizations
12.5 Academic Research Institutions
12.6 Other End Users

13 Company Profiles
13.1 Overview
13.2 Abbott Laboratories
13.2.1 Company Overview
13.2.2 Role of Abbott Laboratories in the Global Solid Tumor Testing Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 ARUP Laboratories
13.3.1 Company Overview
13.3.2 Role of ARUP Laboratories in the Global Solid Tumor Testing Market
13.3.3 SWOT Analysis
13.4 ASURAGEN, INC.
13.4.1 Company Overview
13.4.2 Role of ASURAGEN, INC. in the Global Solid Tumor Testing Market
13.4.3 SWOT Analysis
13.5 Bio-Rad Laboratories, Inc.
13.5.1 Company Overview
13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Solid Tumor Testing Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Beijing Genomics Institute (BGI) Genomics Co., Ltd
13.6.1 Company Overview
13.6.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Solid Tumor Testing Market
13.6.3 SWOT Analysis
13.7 F. Hoffmann-La Roche Ltd.
13.7.1 Company Overview
13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Solid Tumor Testing Market
13.7.3 Financials
13.7.4 Key Insights About Financial Health of the Company
13.7.5 SWOT Analysis
13.8 Guardant Health
13.8.1 Company Overview
13.8.2 Role of Guardant Health in the Global Solid Tumor Testing Market
13.8.3 Financials
13.8.4 SWOT Analysis
13.9 Illumina, Inc.
13.9.1 Company Overview
13.9.2 Role of Illumina, Inc. in the Global Solid Tumor Testing Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.1 Invivoscribe, Inc.
13.10.1 Company Overview
13.10.2 Role of Invivoscribe, Inc. in the Global Solid Tumor Testing Market
13.10.3 SWOT Analysis
13.11 Invitae Corporation
13.11.1 Company Overview
13.11.2 Role of Invitae Corporation, Inc. in the Global Solid Tumor Testing Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 Laboratory Corporation of America Holdings
13.12.1 Company Overview
13.12.2 Role of Laboratory Corporation of America Holdings in the Global Solid Tumor Testing Market
13.12.3 Financials
13.12.4 SWOT Analysis
13.13 NeoGenomics Laboratories, Inc.
13.13.1 Company Overview
13.13.2 Role of NeoGenomics Laboratories, Inc. in the Global Solid Tumor Testing Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 Opko Health
13.14.1 Company Overview
13.14.2 Role of Opko Health, Inc. in the Global Solid Tumor Testing Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 OmniSeq
13.15.1 Company Overview
13.15.2 Role of OmniSeq in the Global Solid Tumor Testing Market
13.15.3 SWOT Analysis
13.16 QIAGEN N.V.
13.16.1 Company Overview
13.16.2 Role of QIAGEN N.V. in the Global Solid Tumor Testing Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Quest Diagnostics Incorporated
13.17.1 Company Overview
13.17.2 Role of Quest Diagnostics Limited in the Global Solid Tumor Testing Market
13.17.3 Financials
13.17.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/2otjgb

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900